In a study concentrating on the use of magic mushrooms in Canada, nearly 80% of the respondents expressed their opinion that psilocybin should be available as a medicinal option for patients in distress. Moreover, approximately two-thirds of the Canadian participants in the study concurred that psilocybin should be legal for those in need.
Beyond just making the substance more accessible, an impressive 84.8 percent of participants feel that the public health system should bear the expenses of such therapies. Psilocybin is seen as a viable choice by a majority of Canadians, especially for alleviating end-of-life distress.
[toc]
Key Findings:
- Citizens of Québec, Ontario, Alberta, and British Columbia perceive psilocybin as a legitimate medical treatment for addressing end-of-life existential distress.
- Magic mushrooms are deemed safe for treating existential distress.
- Participants in two double-blind trials noted immediate and long-lasting benefits, with impacts persisting for six months or more.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, surfaces when individuals face their mortality. Such individuals may witness feelings of helplessness, isolation, anxiety, and a lack of purpose and significance. This type of distress particularly impacts patients with life-threatening diseases, possibly leading to suicidal thoughts or a wish to hasten death.
Generally, individuals grappling with terminal diseases or significant life changes are the ones who frequently experience this kind of distress. It severely impacts their mental health and overall life quality.
Existential therapy aims to address issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. This approach may necessitate multiple sessions and might not be beneficial for everyone.
The doubt regarding the effectiveness of such therapy is a leading reason why many individuals seek alternative treatments.
The Stance of Health Canada on Psilocybin as a Therapeutic Option
Over the last two decades, preliminary clinical trials have highlighted the promising advantages of psychedelic substances in managing complex mental disorders. Specifically, psilocybin has demonstrated a quick and long-lasting reduction of existential distress in patients who are approaching life’s end.
With the recognition of the potential efficacy of these suggested hallucinogenic mushrooms, especially when conventional treatments do not suffice, Health Canada revised the Special Access Program in 2022. This revision permits healthcare professionals to request controlled substances for their patients.
Canadian Support for Access to Psilocybin
An article in the Palliative Care Journal evaluates societal views on psilocybin-assisted therapy for end-of-life care. The data from the study includes:
| Methodology | Input from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of whom had prior experience with psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% deem psilocybin-assisted therapy as a legitimate medical option for treating end-of-life existential distress. 63.3% advocate for the integration of psilocybin into medical treatment. 84.8% support the delivery of this therapy by the public health system. 44.2% believe that healthcare professionals should administer the substance without Health Canada’s supervision. |
These outcomes align with surveys from Canada, England, and Australia. The investigators stressed that their study is distinctive because it focuses on the use of psychoactive substances to alleviate existential distress in end-of-life situations.
Reasons for Canadian Endorsement of Psilocybin Use
An increasing number of Canadians are accepting the use of psilocybin for treatment, primarily due to outcomes from reputable research institutions. Another influential factor is the perceived safety of psilocybin mushrooms in mitigating existential distress. Participants across different studies have not reported severe adverse health effects, such as multi-organ failure.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients were administered a high dose of psilocybin along with a low dose as an active placebo control | Immediate and prolonged The effectiveness of this therapy is primarily credited to mystical experiences that evoke a feeling of unity and profound emotional revelations, which contribute to its benefits that can last for up to six months or even longer. |
| Trial at New York University | 29 patients were randomly selected for the trial and were given either psilocybin or the active placebo niacin | The results of the study echoed the findings of the Johns Hopkins research. Those participants who received psilocybin reported a sense of psychological relief and developed a new outlook on life and death. |
| BMC Palliative Care | The study involved nineteen participants, including 7 doctors, 4 practicing nurses, 4 chaplains, 3 social workers, and a psychologist. The aim was to gain insights into how professionals in palliative care perceive existential distress and their opinions on psychedelic therapy as a potential treatment. | The interviewed palliative care professionals opined that psychedelic-assisted therapy (PAT) could potentially alleviate existential distress. |
Patient Experiences
Aside from scientific studies, numerous accounts from patients also testify to the effectiveness of psilocybin, further highlighting its potential to improve mental health and overall quality of life.
The Journey of Yokoi
Mio Yokoi, diagnosed with terminal stage 4 pancreatic cancer, shares her transformative experience during her therapy. She visualizes herself on a raft, surrounded by nature, and in the company of whimsical creatures. This vision imparts a profound sense of the universe’s interconnectedness and support, engendering deep peace and affirmation within her.
Despite availing conventional mental health support, Yokoi was still plagued by severe anxiety and distress post her diagnosis. However, psilocybin therapy enabled her to reconnect with her body and experience a tangible sense of love and support, significantly improving her mental and emotional wellbeing.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. She was working full-time as an administrative supervisor in healthcare during the study and identified herself as an atheist. She was found to have Generalized Anxiety Disorder during her screening.
Chrissy noted a significant decrease in her anxiety, depression, fear of death, hopelessness, and demoralization. When asked if her religious or spiritual beliefs had changed since her therapy session, she stated that the experiences had brought depth and authenticity to her beliefs.
Brenda’s Journey
Brenda, a woman in her sixties, was diagnosed with stage I colon cancer. During her screening, it was revealed that she had never consumed hallucinogens and was diagnosed with Chronic Adjustment Disorder, coupled with Anxiety.
During her therapy, Brenda experienced the sensation of dying twice. These experiences resulted in her no longer fearing death, but recognizing it as an essential part of life’s journey. She recognized the study as the catalyst for her journey of healing from her childhood trauma. Her data reflected this significant change.
Increased spirituality and decreased anxiety and fear of death were observed.
Availability of Magic Mushroom Products in Canada
At present, access to psilocybin capsules and other products designed to alleviate existential distress or other mental health problems may be limited. However, reliable online dispensaries serve as a good source for these products when needed.
| Feature | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some nearby South American countries. | Discovered in Cambodia, near the Angkor Wat Temple. | Related to the Penis Envy mushrooms, which became popular in the 1970s. |
| Potency | Moderate potency, suitable for beginners. | Moderate potency as well, perfect for those new to the experience. | Highly potent, recommended for those with intermediate to advanced experience. |
| Effects | Causes a mental buzz, slight disorientation, enhanced color perception, euphoria, spiritual experiences, increased creativity, and improved focus. | Evokes an energizing and long-lasting high, minor visual alterations, increased creativity, euphoria, a smooth physical high, fractal images, and feelings of happiness. | Induces intense shamanic experiences, vision quests, profound mystical experiences, enhanced creativity, focus, social awareness, and mood enhancement. |
Mitigating End-of-life Discomfort with Psilocybin Products
Existential or end-of-life distress can cause significant stress for many patients nearing the end of their lives. Traditional treatments may not always be effective, leading to a rise in support within Canada for increased public healthcare access to magic mushrooms. This increased public interest could
We urge regulatory authorities to recognize the potential of magic mushrooms as a valid alternative treatment. For your psychedelic needs and magic mushroom delivery, choose Magic Mushrooms Montreal Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
The outcome of Psychedelic-assisted therapy (PAT) can greatly vary among patients. To ensure a favorable experience, it is crucial to prepare adequately and follow certain guidelines. Patients must undergo thorough screening and mental readiness exercises prior to ingesting the substance.
- Preparation for the Session: Patients are thoroughly evaluated. The therapist discusses the patient’s goals and expectations to set the intentions for the session. The therapist also elucidates the potential effects and what the patient can expect during the session.
- The Session: Patients receive a controlled dose of the substance in a serene, distraction-free environment designed to promote relaxation and introspection. Throughout the session, the therapist provides ongoing support and guidance.
- Post-Session Integration Therapy: This therapy helps patients comprehend and assimilate their experiences. Subsequent sessions offer continued support and counselling to reinforce the insights and transformations achieved during therapy.
How does psilocybin affect the brains of patients in distress?
By binding to serotonin receptors, particularly the 5-HT2A receptor, psilocybin interacts with the brain. This interaction can alter perception, mood, and cognition, leading to substantial shifts in consciousness, emotional breakthroughs, and novel viewpoints.
Is psilocybin therapy available to everyone?
Psilocybin therapy isn’t appropriate for everyone. Patients with certain mental health conditions or existential distress are carefully screened to rule out those with a history of psychosis.
Related Articles:
